Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07312396

An Exploratory Clinical Study on the Protective Effect of Cycling on the Ankle Joint in Gout

This study divided the enrolled gout patients into a jogging group and a cycling group to investigate 1）the effectiveness of cycling intervention in reducing the recurrence risk of gouty ankle arthritis compared with jogging. 2) To clarify the influence of different exercise patterns on the ultrasonic manifestations of gouty ankle arthritis; 3) Clarify the impact of different exercise methods on the blood uric acid levels of gout patients;

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Gout Arthritis Arthritis Arthritis, Gouty Behavior Congenital, Hereditary, and Neonatal Diseases and Abnormalities Crystal Arthropathies Cycling Genetic Diseases, Inborn Gout Joint Diseases Metabolic Diseases Metabolism, Inborn Errors Motor Activity Musculoskeletal Diseases Nutritional and Metabolic Diseases Physical Activity Purine-Pyrimidine Metabolism, Inborn Errors Rheumatic Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • meets the diagnostic criteria for gout of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) in 2015
  • There have been two histories of gout attacks on either side of the ankle joint in the past six months
  • Ultrasound examination within the past 6 months indicated that either ankle joint had characteristic ultrasound manifestations (double-track sign, and/or hyperechoic aggregates, and/or tophi, and/or bone destruction)
  • Those who have had an interval of at least 4 weeks since the most recent acute gout attack
  • If the patient is undergoing uric acid-lowering drug treatment, the drug dosage must remain stable for more than 4 weeks. During the study period, the uric acid-lowering drug regimen or dosage will not be adjusted
  • For women who have the potential to become pregnant, a pregnancy test must be negative, they must not be in the lactation period, and it must be confirmed that they are receiving contraception approved by the researcher and agree to maintain this contraceptive measure throughout the study process
  • Those who were informed of this study and signed the informed consent form

Exclusion criteria

  • Those who have received intra-articular injections of corticosteroids during an attack within the past three months; Those who have taken colchicine, NSAIDs, glucocorticoids in the past two weeks, or those who need to maintain anti-inflammatory drug treatment for a long time during the follow-up period
  • Joint trauma or other types of arthritis
  • There is a history of joint prosthesis or joint surgery
  • Those who have had acute gout attacks within 4 weeks
  • Patients with secondary gout caused by kidney diseases, blood disorders, or taking certain medications, radiotherapy and chemotherapy for tumors, etc
  • Those with severe and unstable cardiovascular and cerebrovascular diseases (such as unstable angina pectoris, coronary angiogenesis, cerebral angiogenesis, transient ischemic attack, congestive heart failure, etc.) and other diseases that researchers have determined to be acute and difficult to control

Treatment and study plan

Urate-lowering therapy (ULT)

Drug

The treatment with uric acid-lowering drugs remained the same as the standard uric acid-lowering treatment plan at the time of enrollment

Jogging

Behavioral

Participants in the study could exercise on the treadmills in the fitness center or jog outdoors, but both needed to reach a moderate intensity. Each total exercise session lasts between 45 and 60 minutes (including 5 to 10 minutes of warm-up time, no less than 20 minutes of exercise time reaching 65% to 75% of the maximum heart rate, and 10 to 15 minutes of cool-down exercise/muscle stretching time).

Cycling

Behavioral

Participants in the study could use the cycling equipment at the fitness center for exercise or do cycling outdoors, but both needed to reach a moderate intensity. Each total exercise session lasts between 45 and 60 minutes (including 5 to 10 minutes of warm-up time, no less than 20 minutes of exercise time reaching 65% to 75% of the maximum heart rate, and 10 to 15 minutes of cool-down exercise/muscle stretching time).

Primary outcomes

  1. The frequency of gout attacks

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. blood uric acid

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Gouty arthritis joint pain score

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Ankle joint magnetic resonance

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Ankle joint ultrasound

    Time frame: From enrollment to the end of treatment at 24 weeks

Other outcomes

  1. Incidence and severity of adverse events/serious adverse events

    Time frame: From enrollment to the end of treatment at 24 weeks

Sponsors and collaborators

Lead sponsor

Zhu Xiaoxia

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Dec 31, 2025
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.